RxDoctor Payments Data

Chris Shin, MD

Internal Medicine · Anaheim, CANPI 1326060179

Payments from drug & device makers

$1,586in general payments, 2019–2025

Across 63 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$408
  • Gilead$346
  • Lilly USA, LLC$271
  • Novo Nordisk$130
  • AbbVie$99
  • Aimmune Therapeutics, Inc.$75
  • plus $259 from 9 others

What the payments were for

  • Food & beverage$1,586100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,586 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$159,760
Medicare patients
276
Services billed
2,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase106$120,481
JardianceEmpagliflozin72$62,915
JanuviaSitagliptin Phosphate73$60,018
ZenpepLipase/Protease/Amylase39$54,970
FarxigaDapagliflozin Propanediol63$50,547
VascepaIcosapent Ethyl105$40,670
JanumetSitagliptin Phos/Metformin Hcl60$39,957
LinzessLinaclotide65$38,198
TrulicityDulaglutide29$32,314
EliquisApixaban45$30,814
TradjentaLinagliptin43$28,384
ProliaDenosumab14$24,191
OzempicSemaglutide25$23,231
MounjaroTirzepatide14$17,961
EntrestoSacubitril/Valsartan13$13,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$99$171,731187 claims
Boehringer IngelheimJardiance, Tradjenta$56$91,299115 claims
Aimmune Therapeutics, Inc.Zenpep$75$54,97039 claims
AstraZenecaFarxiga$40$50,54763 claims
Lilly USA, LLCTrulicity, Mounjaro$271$50,27543 claims
Novo NordiskOzempic$130$23,23125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →